Lentiviral vector production

Scalable solutions to maximize titers

Whether you’re working with an adherent system or involved in suspension production, viral production can be a costly part of your overall operation. Our goal is to maximize your titer and ensure you have a cost-effective scalable solution for viral production.

We are dedicated to your commercial success and that is why we are continuing to develop new solutions to help ensure you stay at the forefront of cell and gene therapy.

Request informationNeed GMP? Contact us

 Download the brochure

Optimized for lentiviral production in suspension culture

Gibco LV-MAX Lentiviral Production System

  • High titers—greater than 1 x 108 TU/mL (unconcentrated LVVs-GFP)
  • Scalable suspension system— from a 96 deep-well plate to a 2L bioreactor
  • Serum free—eliminating animal-origin components and associated risks
  • Active GMP development program
Gibco LV-MAX Lentiviral Production System

The Gibco LV-MAX Lentiviral Production System is the first optimized system that provides all the high-quality components you need to maximize your lentiviral production in suspension cultures in a chemically defined, serum-free environment. 

Multi-component system optimized for improved lentivirus production

The LV-MAX Lentiviral Production System provides a scalable and high-yield lentiviral vector production platform. It is based on a high-density suspension culture of HEK 293–derived viral production cells in LV-MAX Production Medium. Optimal viral titers are mediated by our advanced lipid nanoparticle transfection reagent in combination with a novel lentivirus-specific enhancer and supplement (Figure 1). All components work synergistically to help generate superior, functional lentiviral particles under xeno-free conditions compared to conventional polyethylenimine (PEI), serum-based culture systems (Figure 2). These data highlight the positive impact of using our complete system to maximize production of lentiviral vectors (LVV) compared to titers obtained when using incomplete or non-optimized systems (Figure 3).

Click image to enlarge

Figure 1. LV-MAX Lentiviral Production System protocol overview.

Click image to enlarge

Figure 2. Significantly higher viral titers with LV-MAX system. Lentivirus was produced in 30 mL shaker flasks using our LV-MAX Lentiviral Production System or alternative transfection reagents and cells. LV293 = Gibco viral production cells (HEK 293–derived suspension cells), 293F = Gibco FreeStyle 293-F cell line, PEI = polyethylenimine.

Get improved lentivirus production for less cost

The LV-MAX system produced up to 15 times more virus than the PEI-mediated system in adherent cells and up to 10x more virus than in suspension cells, resulting in over 50% cost reduction compared to PEI-based lentiviral production methods.

Click image to enlarge

Current production method Switch to LV-MAX system and save*
Adherent PEI 58%
Suspension PEI 52%
* Cost comparison based on list price in USD and LV yield of 1 x 108 TU/mL using LV-MAX and 1 x 107 TU/mL using PEI-based adherent and suspension methods. Cost consideration includes media, transfection reagents, and culture vessels.

Figure 3. Lentivirus titers are dramatically improved using LV-MAX Lentiviral Production System. Unfiltered lentivirus produced by suspension cells using the LV-MAX Lentiviral Production System was compared with PEI-mediated transfection of lentiviral vectors in adherent HEK 293T/FT cells and suspension HEK293 cells. The lentiviral titer was determined by transducing HT1080 cells and analyzing GFP-positive cells. The resulting cost savings is also shown.

Scale-up with confidence

The LV-MAX Lentiviral Production System is designed to support robust lentiviral production in a variety of suspension culture vessels. You can scale up or down based on your needs for greater throughput early in discovery or for seamless and efficient scale-up while maintaining high yield in a serum-free system (Figure 4). Regardless of scale, you can produce with more confidence.

Click image to enlarge

Figure 4. Scalability of LV-MAX Lentiviral Production System in HEK 293–derived suspension cells. Lentiviruses were produced in different volumes ranging from a 96 deep-well plate to a 2 L bioreactor using LV-MAX Lentiviral Production System. The lentiviral titer was determined by transducing HT1080 cells and analyzing GFP-positive cells; similar titers were observed in different volume formats.


Advanced lipid nanoparticle technology for superior lentiviral production in adherent cultures

Invitrogen Lipofectamine 3000 Transfection Reagent is a highly efficient, cost-effective tool for lentiviral production. This versatile reagent enables high viral titers even with genes that are large or difficult to package.

Invitrogen Lipofectamine 3000 Reagent

  • High titers—including genes that are large or difficult to package
  • Gentle—reduced reagent dose for improved cell viability
  • Flexible—compatible with your existing protocol
  • Cost-effective—use less ancillary components and labor
Invitrogen Lipofectamine 3000 reagent

In a side-by-side comparison between Lipofectamine 3000 Reagent, Lipofectamine 2000 Reagent and PEI, Lipofectamine 3000 reagent–mediated lentiviral production was ~5–10 times greater than that obtained from the other transfection reagents (Figure 5).

Click image to enlarge

Figure 5. Lentivirus production in adherent cells with Lipofectamine 3000 reagent. pLenti6.3/V5-GW/EmGFP and Invitrogen ViraPower Lentiviral Packaging Mix were delivered by Lipofectamine 3000 reagent, Lipofectamine 2000 reagent, and PEI in a 6-well culture plate with HEK 293T/FT cells. The lentiviral titer was determined by transducing HT1080 cells and analyzing GFP-positive cells.



Scientific posters

Application notes

User manuals

Related products

Custom services


Support Center

  • Lentiviral Gene Delivery for Mammalian Expression Support
    Explore our resources, tip and tricks, and troubleshooting advice for delivering your lentiviral construct into mammalian cells for expression of your protein of interest. Obtain detailed information on every step of the workflow, including preparation of the lentiviral construct, generation of the lentiviral stock, viral titering, transduction, and analysis of expression.

Technical questions?